William James, a partner in Goodwin's IP Litigation Group, explains why the FDA elected to take Sandoz Inc.'s latest application for its etanercept biosimilar to an advisory committee to get its advice on whether to license the product.
Read the full Scrip article here.
Related Content
- InsightNovember 30, 2023
How To Reduce the Risk of Copyright Infringement When Using Generative AI To Write Code
- InsightOctober 31, 2023
Coding with AI in an Open-Source World
- AlertAugust 30, 2023
In re Cellect: Federal Circuit Opens New Path for Double Patenting Challenges
- AlertAugust 29, 2023
Biden Executive Order Puts Focus on Domestic Manufacturing of Inventions Created Using Federal Funding
- AlertJuly 17, 2023
Sens. Tillis and Coons Propose New Legislation Regarding Patentability Under § 101
- AlertJune 28, 2023
MetaBirkins Post-Trial Ruling Clarifies Line Between Trademark Infringement and Free Expression and Grants Broad Injunctive Relief
- AlertJune 9, 2023
Supreme Court Limits Expression-Based Defenses to Trademark Claims
- InsightMay 24, 2023
Top IP, FDA, and Compliance Issues for Medtech Companies Transitioning to Data-Enabled Product Solutions
- Speaking EngagementsFebruary 16, 2024
Utah Bar Association – Intellectual Property Law Summit
- Speaking EngagementsFebruary 8, 2024
FCBA Program on 2023 Patent Law Year in Review
- WebinarDecember 14, 2023
Litigation Financing Demystified: Insights from Funders and Counsel
- WebinarDecember 12, 2023
Contracting Away Your IP Rights: Pitfalls to Avoid With Third Party Partners During Drug Development
- WebinarNovember 29, 2023
Cell and Gene Therapies and Section 112: An Overview of the State of §112 Law and Considerations for Developers of Cell and Gene Therapies
- Speaking EngagementsNovember 29, 2023 | 10:00 AM - 10:45 AM PT
CenterForce's Business Development Summit: Diverse Partners & Associates
- In the PressNovember 20, 2023
California Supreme Court Review: October 2023 (Daily Journal)
- Press ReleaseNovember 17, 2023
Miro acquires Freehand app from InVision